SGLT2 inhibition--a novel strategy for diabetes treatment
- PMID: 20508640
- DOI: 10.1038/nrd3180
SGLT2 inhibition--a novel strategy for diabetes treatment
Abstract
Inhibiting sodium-glucose co-transporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. Genetic mutations in the kidney-specific SGLT2 isoform that result in benign renal glycosuria, as well as preclinical and clinical studies with SGLT2 inhibitors in type 2 diabetes, support the potential of this approach. These investigations indicate that elevating renal glucose excretion by suppressing SGLT2 can reduce plasma glucose levels, as well as decrease weight. Although data from ongoing Phase III trials of these agents are needed to more fully assess safety, results suggest that the beneficial effects of SGLT2 inhibition might be achieved without exerting significant side effects--an advantage over many current diabetes medications. This article discusses the role of SGLT2 in glucose homeostasis and the evidence available so far on the therapeutic potential of blocking these transporters in the treatment of diabetes.
Similar articles
-
A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.Discov Med. 2011 Mar;11(58):255-63. Discov Med. 2011. PMID: 21447284 Review.
-
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y. Drugs. 2015. PMID: 25488697 Review.
-
[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].Orv Hetil. 2012 May 6;153(18):695-701. doi: 10.1556/OH.2012.29351. Orv Hetil. 2012. PMID: 22547464 Review. Hungarian.
-
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. doi: 10.1210/jc.2009-0473. Epub 2009 Nov 5. J Clin Endocrinol Metab. 2010. PMID: 19892839 Review.
-
Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Drugs. 2010. PMID: 20205482 Review.
Cited by
-
A novel SGLT is expressed in the human kidney.Eur J Pharmacol. 2012 Sep 5;690(1-3):77-83. doi: 10.1016/j.ejphar.2012.06.033. Epub 2012 Jul 3. Eur J Pharmacol. 2012. PMID: 22766068 Free PMC article.
-
Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient.Cureus. 2023 Dec 27;15(12):e51184. doi: 10.7759/cureus.51184. eCollection 2023 Dec. Cureus. 2023. PMID: 38283482 Free PMC article.
-
Clinically and pharmacologically relevant interactions of antidiabetic drugs.Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83. doi: 10.1177/2042018816638050. Epub 2016 Mar 31. Ther Adv Endocrinol Metab. 2016. PMID: 27092232 Free PMC article. Review.
-
Structural mechanism of a dual-functional enzyme DgpA/B/C as both a C-glycoside cleaving enzyme and an O- to C-glycoside isomerase.Acta Pharm Sin B. 2023 Jan;13(1):246-255. doi: 10.1016/j.apsb.2022.05.022. Epub 2022 May 25. Acta Pharm Sin B. 2023. PMID: 36815035 Free PMC article.
-
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.Clin Mol Hepatol. 2022 Oct;28(4):725-738. doi: 10.3350/cmh.2022.0015. Epub 2022 Mar 14. Clin Mol Hepatol. 2022. PMID: 35286799 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases